Proposal for new diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis by unknown
REVIEW Open Access
Proposal for new diagnostic criteria for DIC
from the Japanese Society on Thrombosis
and Hemostasis
Hidesaku Asakura1* , Hoyu Takahashi2, Toshimasa Uchiyama3, Yutaka Eguchi4, Kohji Okamoto5, Kazuo Kawasugi6,
Seiji Madoiwa7, Hideo Wada8 and DIC subcommittee of the Japanese Society on Thrombosis and Hemostasis
Abstract
Disseminated intravascular coagulation (DIC) is a serious disease that, in the presence of underlying disease, causes
persistent, generalized, marked coagulation activation. Early treatment based on an appropriate diagnosis is very
important for improving patients’ prognosis, to which end diagnostic criteria play a key role. Several criteria have
been proposed, but each has its strengths and weaknesses, and improved criteria are needed. Widespread use of
coagulofibrinolytic markers has elucidated that the pathology of DIC differs greatly as a function of the underlying
disease. Thus, discriminating use of DIC diagnostic criteria that take underlying diseases into account is important.
DIC diagnostic criteria that are well known in Japan include the Japanese Ministry of Health and Welfare’s old DIC
diagnostic criteria (JMHW criteria), the International Society on Thrombosis and Haemostasis’s DIC diagnostic criteria
(ISTH criteria), and the Japanese Association for Acute Medicine’s acute-stage DIC diagnostic criteria (JAAM criteria).
Those criteria have their respective drawbacks: the sensitivity of the ISTH criteria is poor, the JAAM criteria cannot
be applied to all underlying diseases, and the JMHW criteria have poor sensitivity in the case of infections, do not
use molecular markers, and result in misdiagnosis. The Japanese Society on Thrombosis and Hemostasis’s newly
proposed provisional draft DIC diagnostic criteria (new criteria) use diagnostic criteria classifications of
“hematopoietic disorder type”, “infectious type”, and “basic type” based on the underlying pathology. For the
hematopoietic disorder type the platelet count is omitted from the score, while for the infectious type, fibrinogen is
omitted from the score. Also, points are added if the platelet count decreases with time. In the new criteria,
molecular markers and antithrombin activity have been newly included, and as a countermeasure for misdiagnosis,
3 points are deducted if there is liver failure. In this paper, we discuss various problems encountered with DIC
diagnosis, and we describe the new criteria together with the events that led to their creation.
These new diagnostic criteria take into account the underlying diseases of wide area, and we expect that they will
serve clinicians well due to the above adaptations and improvements.
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Background
Disseminated intravascular coagulation (DIC) is a serious
disease that, in the presence of underlying disease, causes
persistent, generalized, marked coagulation activation and
frequent formation of microthrombi in microvessels. Both
coagulation activation and fibrinolytic activation are seen,
but the severity of the fibrinolytic activation differs consid-
erably as a function of the underlying disease(s). Progres-
sion of DIC causes decreases in hemostatic factors such as
platelets and clotting factors and leads to consumption
coagulopathy [1–5]. The two major symptoms of DIC are
bleeding symptoms and organ symptoms, and the progno-
sis becomes very poor if the clinical symptoms become
apparent. For that reason, it is ideal to initiate treatment
of DIC before clinical symptoms manifest.
The Scientific Standardization Committee (SSC) of
the International Society on Thrombosis and Haemo-
stasis (ISTH) defined DIC as follows: “DIC is an ac-
quired syndrome characterized by the intravascular
activation of coagulation with loss of localization aris-
ing from different causes. It can originate from and
cause damage to the microvasculature, which if suffi-
ciently severe, can produce organ dysfunction” [6]. The
view of the ISTH can be considered to represent the
world’s general perception regarding DIC. In fact, the
pathology of DIC complicated by sepsis or some other
severe infection is accurately presented. However, serious
bleeding symptoms may occur due to marked fibrinolytic
activation, as in the case of DIC secondary to acute
leukemia (especially acute promyelocytic leukemia), aortic
aneurysm, giant hemangioma, placental abruption, and
metastatic prostate cancer. Although organ symptoms
are usually not seen, there is a problem in that consid-
eration has not been given to DIC with severe bleeding
symptoms [7, 8].
DIC is a serious condition, and early treatment based
on an appropriate diagnosis is very important for im-
proving patients’ prognosis, in which effective diagnostic
criteria play a key role. In this paper, we discuss the di-
versity in DIC, as well as various problems encountered
with DIC diagnosis, and describe the provisional draft
DIC diagnostic criteria that have been proposed by the
Japanese Society on Thrombosis and Hemostasis (JSTH)
(the new criteria).
Review
DIC disease type classification
There are various DIC disease types, depending on the
underlying disease. The concept of DIC disease type clas-
sification is important to understanding that diversity [9].
Marked coagulation activation is the primary pathology of
DIC and seen in all cases, but in regard to other aspects,
the pathology (especially the degree of fibrinolytic activa-
tion) differs considerably as a function of the underlying
disease. The degree of fibrinolytic activation is controlled
by plasminogen activator inhibitor-1 (PAI-1), which is one
of the important factors characterizing DIC.
In suppressed-fibrinolytic-type DIC, coagulation acti-
vation is high, whereas fibrinolytic activation remains
mild. This type of DIC is seen in cases complicated by
sepsis. Lipopolysaccharide (LPS) and inflammatory cyto-
kines act on the vascular endothelium, thereby enhan-
cing production of fibrinolysis inhibitory factor PAI-1
and creating a potent state of inhibition of fibrinolysis.
Dissolution of multiple microthrombi becomes difficult,
increasing the risk of organ failure due to failure of the
microcirculation, but bleeding symptoms are relatively
mild. Laboratory findings include elevated levels of
thrombin-antithrombin complex (TAT), soluble fibrin
(SF), and prothrombin fragment 1 + 2 (F1+2), which are
coagulation activation markers, but plasmin-α2-plasmin
inhibitor complex (PIC), a fibrinolytic activation marker, is
only slightly elevated [10, 11]. Other characteristic find-
ings are relatively mild increases in fibrin/fibrinogen
degradation products (FDP) and D-dimer, which reflect
lysis of microthrombi. Intrinsically, α2-plasmin inhibitor
(α2PI) is consumptively decreased in DIC. However, in
suppressed-fibrinolytic-type DIC, α2PI is generally slightly
below or almost normal because plasmin production is
low, and α2PI is a protein that increases in inflammation.
FDP and D-dimer are recognized as the most important
markers for DIC diagnosis. However, in suppressed-
fibrinolytic-type DIC, it is not unusual for their elevation
to be mild, leading to concern that diagnosis of DIC might
be delayed if too much emphasis is placed only on these
markers. Conversely, early diagnosis is possible if attention
is paid to elevation of TAT and SF as blood markers,
together with a decrease in the platelet count with time.
Because of the inflammatory reaction, fibrinogen often
does not decrease.
Enhanced-fibrinolytic-type DIC is characterized by
marked fibrinolytic activation that is out of balance
with coagulation activation. Characteristic patients have
underlying diseases such as acute promyelocytic leukemia
(APL), aortic aneurysm, and prostate cancer. PAI-1 is
hardly elevated, while the strong fibrinolytic activation
and hemostatic plugs (thrombi for hemostasis) are readily
dissolved. As a result, bleeding symptoms are likely to be
severe, but organ failure is almost never seen. In APL and
some cancers, annexin II is involved in strong fibrinolytic
activation [12, 13]. Laboratory findings include marked
increases in the coagulation activation markers, TAT
(SF, F1+2), and the fibrinolytic activation marker, PIC,
while FDP and D-dimer (especially FDP) are also in-
creased [10, 11]. It is also characteristic for fibrinogen
and α2PI to be markedly decreased. Even if the platelet
count is only slightly decreased, caution is needed in
regard to potential massive bleeding. Furthermore,
Asakura et al. Thrombosis Journal  (2016) 14:42 Page 2 of 13
when treating enhanced- fibrinolytic-type DIC, it is not
unusual for administration of only a heparin to pro-
mote bleeding, and in such cases it is effective to con-
comitantly administer nafamostat mesylate (a potent
anti-thrombin agent that also has anti-plasmin activity)
or tranexamic acid with a heparin [14–17].
Balanced-fibrinolytic-type DIC is characterized by
balance between the coagulation and fibrinolytic activa-
tions and is thus an intermediate pathology between the
two types of DIC described above. With the exception of
advanced cases, bleeding symptoms and organ symptoms
are relatively rare. Although this type is seen in many DIC
cases with solid cancers, in the case of some cancers such
as prostate cancer and blood vessel-associated malig-
nant tumors, the disease type is enhanced-fibrinolytic-
type DIC.
Gando et al. reported that DIC seen at the time of
trauma is DIC with the fibrinolytic phenotype in which
the initial fibrinolytic activation is high, but at 24–48 h
post-trauma, the pathology changes to a thrombotic
phenotype due to the activity of PAI-1 [18, 19]. For DIC
caused by trauma, the fact that tranexamic acid is used
only at the time of enhanced-fibrinolytic-type DIC can
be considered to be the point. The concept is that DIC
with the fibrinolytic phenotype is close to enhanced-
fibrinolytic-type DIC, while DIC with the thrombotic
phenotype is close to suppressed-fibrinolytic-type DIC.
The commonly used conventional animal models of
DIC are induced with LPS or tissue factor (TF) (espe-
cially LPS), but the actual situation is that little con-
scious distinction has been made between them as
the same DIC model. However, our group recently
showed that the pathology differs greatly depending on the
DIC inducer used [9]. The LPS-induced DIC model is char-
acterized by a state of suppression of fibrinolysis due to
markedly elevated PAI-1 activity and only mild elevation of
D-dimer. It is easy to pathologically demonstrate multiple
microthrombi. Whereas organ disorders such as hepatore-
nal disorder are advanced, bleeding symptoms are hardly
seen, even though the platelet count and fibrinogen are
markedly reduced [20]. Meanwhile, the TF-induced DIC
model is characterized by only a mild increase in PAI-1
activity, while D-dimer is sharply increased, reflecting the
fact that there is adequate fibrinolytic activation. It is diffi-
cult to pathologically demonstrate microthrombi due to en-
hanced thrombolysis. Interestingly, whereas there is almost
no hepatorenal failure, severe hematuria is seen as a bleed-
ing symptom. Moreover, the high degree of fibrinolytic acti-
vation results in progression of not only fibrin degradation,
but also fibrinogen degradation [21]. In this way, it can be
thought that the LPS-induced DIC model is similar in
pathology to clinical suppressed-fibrinolytic-type DIC, while
the TF-induced DIC model is pathologically similar to
enhanced-fibrinolytic-type - balanced-fibrinolytic-type DIC.
Representative DIC diagnostic criteria
Three DIC diagnostic criteria are well known in Japan:
the Japanese Ministry of Health and Welfare’s DIC diag-
nostic criteria (JMHW criteria), the ISTH’s DIC diagnos-
tic criteria (ISTH criteria), and the Japanese Association
for Acute Medicine’s DIC diagnostic criteria (JAAM
criteria) [6, 22, 23] (Table 1).
Those criteria have their respective drawbacks, such as
the poor sensitivity of the ISTH criteria and that the
JAAM criteria cannot be applied to all underlying diseases
(e.g., DIC complicated by a hematopoietic malignancy
Table 1 Comparison of existing DIC diagnostic criteria
JMHW ISTH JAAM
Underlying disease Clinical symptoms 1 p
bleeding: 1 p





SIRS score ≥3: 1 p
Platelet count (X104/μL) 8 < − ≤12 : 1 p
5 < − ≤8 : 2 p
≤5 : 3 p
5–10 : 1 p
<5 : 2 p
8 - ≤12 or >30 % reduction/24 h: 1 p
<8 or >50 % reduction/24 h: 3 p
Fibrin-related marker FDP (μg/ml)
10 ≤ − <20: 1 p
20 ≤ − <40: 2 p
≥40 : 3 p
FDP, D-dimer, SF
moderate increase: 2 p
strong increase: 3 p
FDP (μg/ml)
10 ≤ − <25: 1 p
≥25 : 3 p
Fibrinogen
(mg/dl)
100 < − ≤150: 1 p
≤100: 2 p
<100: 1 p None
PT PT ratio







Diagnosis of DIC ≥7 p ≥5 p ≥4 p
p: points
JMHW: JMHW criteria; ISTH: JMHW criteria; JAAM: JMHW criteria; PT: prothrombin time
JMHW criteria: When there is leukemia/related diseases, aplastic anemia, or marked bone marrow megakaryocyte reduction, such as after administration of an
anti-tumor agent, and a high degree of thrombocytopenia, the bleeding symptom and platelet count items should be calculated as 0 points, and DIC is diagnosed
if the score is ≥4 points
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cannot be diagnosed). To date, the JMHW criteria have
the longest history and a solid reputation.
However, the JMHW criteria have also been noted to
have various problems because they have poor sensitivity
in the case of infections, do not use molecular markers
that reflect coagulation activation (which is at the heart of
DIC), and result in misdiagnosis of liver failure. With the
aim of developing better DIC diagnostic criteria, the SSC/
DIC subcommittee of the Japanese Society on Thrombosis
and Hemostasis (JSTH) held numerous discussions over
the years, but a consensus was not reached. For that rea-
son, in July 2012, the JSTH established a committee
charged with creating DIC diagnostic criteria.
That committee also carried out numerous in-depth
discussions, both in meetings and via e-mail exchanges.
The committee had 13 members, consisting of 6 from
the SSC/DIC subcommittee and 7 others. The members
represented various medical fields: internal medicine,
surgery, obstetrics and gynecology, pediatrics, clinical la-
boratory medicine, and emergency medicine. In addition,
the SSC/DIC subcommittee members put in a collective
effort and carried out a thorough literature search.
This culminated, in October 2014, with publication of
the JSTH’s provisional draft DIC diagnostic criteria
(hereinafter, new criteria) [24]. The criteria are consid-
ered to be provisional, because they are likely to be
modified on the basis of the results of future studies.
Since that paper was published in a Japanese journal,
the new criteria remain largely unknown internation-
ally. We hope to remedy that situation through publica-
tion of the present English manuscript.
Basic concept of these DIC diagnostic criteria
Three main methods exist for creating diagnostic cri-
teria. The first method is creation of criteria based on
the definition of DIC. The ISTH’s overt DIC criteria are
equivalent to this. Since DIC is a domain that is
evidence-poor, the approach is to try to create criteria by
defining the portions for which there is no evidence [6].
The second method aims to create criteria that reflect
the prognosis. In fact, most existing diagnostic criteria
reflect the prognosis. No DIC diagnostic criteria have
been drawn up based on prognosis as the endpoint, but
there are a number of papers of DIC diagnostic criteria
that secondarily reflect the prognosis [25–28]. The third
method is to compile cases of DIC diagnosed by experts
and then create diagnostic criteria. The JMHW criteria
used this approach [29, 30].
Because there are no specific markers for DIC, it
makes sense to diagnose DIC using a scoring method
that combines multiple markers that show characteristic
changes in DIC. The DIC clinical practice guidelines of
the United Kingdom, Japan, and Italy that have been
published as academic papers in English all recommend
using a scoring method to diagnose DIC [5, 31–33]. The
JMHW criteria, ISTH criteria, and JAAM criteria all
carry out diagnosis using a scoring method [6, 22, 23]
(Table 1). Japan has a long history of DIC clinical trials
of various drugs that have been performed using the
JMHW criteria. For that reason, it can be thought that,
even when the objective is to create new, improved diag-
nostic criteria, it would be inappropriate to create totally
new criteria, and that the JMHW criteria should be kept
as the core. Thus, even the new criteria must inevitably
use a scoring method.
The background of creation of the JAAM criteria was
that diagnosis by the JMHW criteria was often too late
in the fields of emergency medicine and surgery [29].
However, it was often pointed out that, while the sensi-
tivity of the JAAM criteria is high, their specificity is low
[27], and they also do not incorporate the molecular
markers associated with coagulation activation that
reflect the nature of DIC. Verification of the JAAM cri-
teria was performed by collecting cases in the emergency
medicine field, and it was named the acute phase DIC
diagnostic criteria, but originally the criteria were posi-
tioned only for the emergency medicine field (not all
acute phase). The ISTH criteria were developed by mod-
eling the Japanese JMHW criteria, but they were even
less sensitive than the JMHW criteria [23].
Today, we know from analyses using molecular markers
that the pathology of DIC differs greatly depending on the
underlying disease [7, 9–11]. This means that there are lim-
itations on the ability of any one set of criteria to diagnose
all presentations of DIC. It can be thought that the DIC cri-
teria should be selected and used in the light of a patient’s
underlying disease(s). However, because the numerous clas-
sifications of underlying diseases might complicate DIC
diagnostic criteria, diagnosis should be performed using a
set of criteria for the basic type and then adding different
diagnostic items that are appropriate for the hematopoietic
disorder type and infectious type of DIC. In particular, since
the JMHW criteria are excellent for blood diseases but have
weak diagnostic capacity for infectious diseases, there is a
need for modification to address this point.
With the JMHW criteria, it is not uncommon for a co-
agulation abnormality that is accompanied by liver disease
to be misdiagnosed as DIC, and that has to be considered.
The two major clinical symptoms of DIC are bleeding
symptoms and organ symptoms. However, the clinical
symptoms are non-specific, and it can be difficult to
determine if they are symptoms due to an underlying
disease or a complication other than DIC or are symp-
toms caused by DIC. Also, if no symptoms manifest and
DIC is thus not diagnosed, that is an obstacle to early
diagnosis of the disease. It can thus be thought that the
clinical symptoms used in the JMHW criteria should be
removed from the diagnostic criteria.
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Significance of various markers for DIC diagnosis
FDP, D-dimer
FDP and D-dimer have great significance in the diagnosis
of DIC, and they are, in fact, included as important test
items in almost all DIC diagnostic criteria [6, 22, 29].
However, it must be kept in mind that, while FDP and D-
dimer are high in sensitivity, they are low in specificity.
For example, these markers are often elevated even in
such diseases as deep vein thrombosis, pulmonary
thromboembolism, massive hydrothorax/ascites, and large
subcutaneous hematomas [34–36].
Since FDP and D-dimer do not necessarily coincide
with the molecular species of interest, there is medical
significance in measuring both. For example, not only
fibrin but also fibrinogen is broken down in DIC [37],
and fibrinogen degradation is increased when the fi-
brinolytic system is highly activated. FDP increases
markedly, but D-dimer rises only moderately. This results
in a dissociation phenomenon between FDP and D-dimer
(i.e., the D-dimer/FDP ratio decreases) [13, 37–39]. How-
ever, we should refrain from aimlessly measuring both
FDP and D-dime.
In the case that fibrin/fibrinogen degradation is ad-
vanced due to strong fibrinolytic activation, the reaction
with the D-dimer fraction may be reduced depending on
the D-dimer reagent that is used [39]. Accordingly, for
the DIC diagnostic criteria, it can be thought that em-
phasis should be placed on FDP rather than D-dimer.
Platelet count
As noted earlier, the platelet count cannot be used in the
diagnostic criteria for diagnosis of the hematopoietic dis-
order type, and sufficient caution is necessary in this
regard.
Except for the hematopoietic disorder type, the
platelet count, like FDP and D-dimer, is an important
test item for DIC diagnosis. However, there are also
many patients with a decreased platelet count that is
not due to DIC, and it is necessary to raise awareness
regarding diseases that need to be differentiated from
DIC. A decreased platelet count has high sensitivity
for diagnosis of DIC, but it can be said that its speci-
ficity is low [23, 27, 31, 40].
Changes in the platelet count with time are also im-
portant. For example, even if the platelet count is above
12 × 104/μL, DIC may be present if the count decreases
with time. For this reason, there is significance in assign-
ing a score to the thrombocytopenia rate, separate from
the platelet count [41, 42].
Fibrinogen
For diagnosis of DIC, fibrinogen is a marker with high
specificity, but low sensitivity [29, 30, 43–45]. Especially
in inflammatory diseases, fibrinogen does not decrease
even in patients thought to have DIC, and in some cases
it actually increases [46]. The JAAM criteria were ini-
tially created using fibrinogen for DIC diagnosis at ≥5
points, but in actual application, fibrinogen could not be
shown to have diagnostic significance. The criteria were
thus modified by eliminating fibrinogen for DIC diagno-
sis at ≥4 points [29]. This is probably because the valid-
ation of JAAM criteria was performed in many cases
with concurrent infection. There are underlying diseases
for which fibrinogen is valuable as a marker. For ex-
ample, fibrinogen readily decreases in patients with
hematopoietic malignancies, obstetric complications,
head trauma, aortic aneurysm, and solid cancers, and is
an important finding [47–51].
Against this background, one approach would be to
change the test items in the diagnostic criteria to fit each
underlying disease. That is, in the case that the infec-
tious type is the underlying disease, it is desirable to
exclude fibrinogen, which fluctuates as an acute-phase
reactive protein, from the score.
Prothrombin time (PT)
PT can reflect organ failure, and the prognosis is
poor in patients with an infection and a prolonged
PT [29, 30, 52–55]. On the other hand, since PT is
also prolonged in liver disease and vitamin K defi-
ciency, it is not a characteristic marker for DIC.
Most studies that investigated the sensitivity and specifi-
city of PT in the diagnosis of DIC examined cases of infec-
tion, and almost none examined other underlying diseases
[29, 30, 43, 44, 46]. Ordinarily, verification of significance
of PT in diagnostic criteria should be performed in
various underlying diseases such as infectious disease,
hematopoietic malignancy, and solid cancer. Because
PT has been used for many years and has a proven
track record, it was decided to include it in the new
criteria.
There is a problem as to the notation that should be
used for PT in the new criteria, i.e., PT ratio or INR.
INR values using different PT reagents converge in pa-
tients on warfarin but not in patients with liver disease
or DIC. INR (liver) has been proposed [56, 57], and
these values converges in liver disease but not in DIC. In
the case of using PT for DIC diagnosis, the PT ratio
must be used at present. However, given the current
situation that the INR notation is widely used, if the ISI
of the PT reagent is close to 1, it can be thought that
INR can be substituted for the PT ratio.
Molecular markers of coagulation activation
TAT, SF, and F1+2 are molecular markers that reflect co-
agulation activation, which can be said to be at the heart
of DIC. Incorporation of these molecular markers in
DIC diagnostic criteria can be expected to improve both
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the sensitivity and specificity of the criteria [58–63].
Furthermore, TAT and SF are significant in that, if both
are completely normal, then they can be used for exclu-
sion of the diagnosis, that is, to determine that DIC is
not present. At present, many institutions still do not
measure these markers in-hospital, but that can be
expected to change if they are included in the DIC diag-
nostic criteria. Even institutions that do not perform in-
hospital assays will be able to confirm the test results at
a later date, and it can be thought that this will help re-
duce misdiagnoses.
On the other hand, we can anticipate that contrary
opinions will also be expressed, such as that there are
many institutions that would not get the results for these
molecular markers on the same day, and especially in
pediatric departments, which have many patients for
whom blood sampling is difficult, it is easy for many
false high values to be generated [64].
These molecular markers of coagulation activation were
also subjected to extensive discussions in the JSTH’s com-
mittee for creating DIC diagnostic criteria, and in the end
it was decided to include markers in the criteria because
they had the support of many of the committee members.
However, which molecular markers are the best to be
included has not yet been settled and will require further
discussion. For that reason, it was decided to include all
three of these molecular markers of coagulation activation
in the new criteria. However, the cutoff values for the mo-
lecular markers have yet to be set, and scores were given
based on the degree of elevation above the upper limit of
the standard range. Using the markers for exclusion diag-
nosis also seems to make sense. However, if a minus score
were assigned when a molecular marker remains within
its standard range, there is concern that the diagnosis
might be reversed when test results are returned at a later
date. Accordingly, this approach was not adopted.
Antithrombin (AT) activity
The JSTH’s committee for creating DIC diagnostic cri-
teria discussed many pros and cons regarding incorpor-
ation of AT activity into the criteria.
Multiple committee members expressed opinions
explaining their being in favor of inclusion of AT activity
in the criteria: measurement of AT activity is directly
linked to treatment selection (use of AT concentrate for
DIC finds AT activity in ≤70 % of cases in Japan); in
cases of infection, the sensitivity of DIC diagnosis would
be improved by adopting AT activity; the prognosis
could be evaluated [46, 65–75].
Negative opinions were also expressed by multiple
committee members: it is rare for AT activity to decrease
due to DIC mechanisms, and AT activity is not a specific
indicator for DIC (the diagnostic specificity would be
reduced) [42, 43, 58, 76]; AT activity generally reflects a
protein synthesis disorder in the liver or extravasation
during inflammation; AT activity correlates with serum
albumin [77–80]; the degree of decrease in AT activity
differs with the underlying disease; incorporation would
complicate the diagnostic criteria.
The committee’s conclusion was as follows: AT activity
would be incorporated in the new criteria, but the deci-
sion would be re-visited in the future at a time when the
results of validation of the new criteria are in hand.
Considerations for the fields of obstetrics and pediatrics
In Japan, the obstetric DIC score is frequently used in ob-
stetrics. Obstetric DIC takes a very rapid course and
requires prompt diagnosis and treatment of the under-
lying disease(s) and clinical symptoms. The obstetric DIC
score enables early initiation of treatment and is thus ex-
tremely useful. It is widely used in Japan (The Japan Soci-
ety of Obstetrical, Gynecological & Neonatal Hematology;
http://www.jsognh.jp/dic/). Moreover, since such DIC-
associated markers as FDP, D-dimer, TAT, SF, and F1+2 in-
crease even in normal pregnancy [81], DIC cannot be said
to be present merely because these markers are elevated.
An opinion of committee was expressed that, if the new
criteria become diagnostic criteria consisting mainly of
blood coagulation and fibrinolysis tests, they will not be
able to be applied to obstetric DIC.
Also, an opinion was expressed that, if the new criteria
are based on the JMHW criteria, it is highly likely that
they will not be able to be applied to diagnosis of DIC in
newborn infants. The reason is that some items for
coagulation activation and fibrinolytic activation differ
greatly between newborns and adults. In addition, since
only a limited amount of blood can be drawn from chil-
dren, especially newborns, it is desirable to keep the
number of test items as small as possible. Coagulation
activation-related markers such as TAT and SF, are
prone to show false high values (leading to misdiagnosis)
by ex vivo coagulation for patients for whom blood
collection is difficult (such as children) [64]. The con-
sensus reached on the basis of these opinions was that
the new criteria would not be applied to newborns.
Countermeasures for misdiagnoses
With the JMHW criteria, misdiagnosis readily occurred
for patients showing PT prolongation, decreased fibrino-
gen, and decreased platelet count due to liver failure, as
well as patients with elevated FDP and D-dimer when
they had liver failure and also massive ascites [36]. It is
necessary to make adjustments to avoid misdiagnosis in
liver failure cases.
Other molecular markers
Once DIC has been diagnosed, other markers are known
to be useful for the subsequent steps of disease type
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classification and pathological evaluation. It was thus de-
cided to also include statements regarding “testing and
significance related to DIC diagnosis”.
Various excellent markers are known: PIC and α2PI
are essential markers for evaluating fibrinolytic activa-
tion [7, 9–11]; protein C is an anticoagulant factor for
evaluating the prognosis [74, 82–84]; PAI-1 is a fibrino-
lytic inhibitory factor [73, 85–89]; HMGB-1 is a nuclear
molecule [90, 91]; and e-XDP is a fibrin degradation
product of granulocyte elastase [92–97].
The new DIC diagnostic criteria (JSTH’s provisional draft
DIC diagnostic criteria)
Algorithm of application of the DIC diagnostic criteria
(Fig. 1)
This algorithm should be followed from the time that
DIC is suspected.
Underlying diseases of DIC
Many underlying diseases of DIC are known. Table 2
shows representative underlying diseases. Obstetric com-
plications and even diseases of the newborn are known to
be characteristic underlying diseases of DIC. Specific
examples of obstetric complications include placental
abruption, amniotic fluid embolism, DIC-type afterbirth
bleeding, and eclampsia, while diseases of newborns in-
clude neonatal asphyxia, infection, placental abruption, in
utero death of one fetus in a multiple pregnancy, respira-
tory distress syndrome, and intraventricular hemorrhage.
Fig. 1 Algorithm for applying the DIC diagnostic criteria. Suspicion of DIC (※1): When there is any underlying disease of DIC (Table 2), an unexplained
abnormal laboratory value such as a decreased platelet count, decreased fibrinogen or elevated FDP, or a thrombotic disease such as venous
thromboembolism is evident. The new criteria cannot be applied to obstetric or newborn DIC, and for that reason this is shown as the first step in the
algorithm. Hematopoietic disorder (※2): A positive (+) judgment is made when it is determined that there is some cause besides DIC for a decreased
platelet count, such as bone marrow suppression, bone marrow failure, or platelet destruction or aggregation in the peripheral circulation. For the
hematopoietic disorder type, scoring for the platelet count is not performed. Hematopoietic tumors in a state of remission are judged as negative (−).
In the absence of a hematopoietic disorder, the possibility of an infection is examined. If an infection is present, the diagnostic criteria for the
infectious type are used. Scoring for fibrinogen is not performed for the infectious type. If there is neither a hematopoietic disorder nor an infection,
the diagnostic criteria for the basic type are used. When an underlying disease cannot be specified (or there are many), and neither “hematopoietic
disorder type” nor “infectious type” applies, the diagnostic criteria for the basic type are used. For example, if an infection accompanies a solid cancer,
such that the underlying disease cannot be specified, the diagnostic criteria for the basic type are used
Table 2 Underlying diseases of DIC
1. Infections
• Sepsis
• Other severe infections (of the respiratory organs, urinary tract,
biliary system, etc.)
2. Hematopoietic malignancies
• Acute promyelocytic leukemia (APL)
• Other acute leukemia
• Malignant lymphoma
• Other hematopoietic malignancies
3. Solid cancers (usually advanced cancer with metastasis)
4. Tissue damage: trauma, burns, heat stroke, rhabdomyolysis
5. Post-surgery
6. Vascular-related diseases
• Thoracic and abdominal aortic aneurysms
• Giant hemangioma
• Blood vessel-associated tumors
• Collagen disease (cases of vasculitis complications)
• Other vascular-related diseases
7. Liver injury: acute liver failure, acute hepatitis, liver cirrhosis
8. Acute pancreatitis
9. Shock




Note: There are characteristic underlying diseases of DIC in the fields of
obstetrics and newborns, but they are not shown in this table because these
diagnostic criteria are not applicable to either of those fields
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Representative underlying diseases and pathologies that
must be differentiated
Table 3 shows the representative underlying diseases and
pathologies that must be differentiated from DIC.
DIC diagnostic criteria
The first step is to confirm, according to the algorithm
(Fig. 1), which diagnostic criteria can be applied to the
patient in question, and then proceed to the diagnosis
of DIC using Table 4. For the basic type, scoring should
be performed using the data for the platelet count,
FDP, fibrinogen, PT ratio, AT activity, and coagulation
activation-associated molecular markers (elevation of
TAT, SF, or F1+2). The total score should be calculated,
and a diagnosis of DIC should be made for the basic
type and the infectious type if the total is 6 points or
more and for the hematopoietic disorder type if the
total is four points or more. The point for diagnosis of
DIC in infectious type is more than 6 points though
there is one less item to check with the infectious type
as compared to the basic type. This reason is that de-
pression in fibrinogen is hardly observed in DIC caused
by infection. However, the point for diagnosis of DIC
in infectious type might be modified from 6 points to 5
points after validation of the new DIC diagnostic cri-
teria. Table 4 shows that 3 points are subtracted for
liver failure. Scoring for underlying diseases and clin-
ical symptoms was included in the JMHW criteria [22]
but omitted from the new criteria.
Depending on the value for the platelet count, the
score covered a range of 0 to 3 points (the same range
as in the JMHW criteria), adding another 1 point if a
decrease of ≥30 % is seen within 24 h. However, for a
platelet count of ≤5 × 104/μL, no extra point is added
even if there is a decrease of ≥30 % within 24 h, so the
maximum score for the platelet count is 3 points.
Table 3 Representative underlying diseases and pathologies
that must be differentiated
Decreased platelet count
1. Enhancement of platelet destruction and aggregation
• Thrombotic microangiopathy (TMA): thrombotic thrombocytopenic
purpura (TTP), hemolytic uremic syndrome (HUS), HELLP syndrome,
TMA after hematopoietic stem cell transplantation
• Heparin-induced thrombocytopenia (HIT)
• Idiopathic thrombocytopenic purpura (ITP), systemic lupus
erythematosus (SLE), antiphospholipid antibody syndrome (APS)
• Extracorporeal circulation
2. Pathologies that lead to bone marrow suppression/bone
marrow failure
• Hematopoietic malignancies (acute leukemia, blastic crisis of
chronic myelogenous leukemia, myelodysplastic syndrome, multiple
myeloma, bone marrow infiltration of malignant lymphoma)
• Hemophagocytic syndrome
• Solid cancers (with bone marrow infiltration)
• Chemotherapy or radiation therapy with bone marrow suppression
• Bone marrow suppression due to drugs
• Some viral infections
• Some blood diseases besides hematopoietic malignancies
(aplastic anemia, paroxysmal nocturnal hemoglobinuria,
megaloblastic anemia)
3. Liver failure, cirrhosis, hypersplenism
4. Sepsis













1. Congenital afibrinogenemia, congenital hypofibrinogenemia,
dysfibrinogenemia
2. Liver failure, malnutrition
3. Drug-induced: L-asparaginase, corticosteroids, fibrinolytic therapy
4. False lowering: at the time of administration of drugs with anti-
thrombin action (e.g., dabigatran)
Prothrombin time prolongation
1. Vitamin K deficiency, oral warfarin
2. Liver failure, malnutrition
3. Deficiency or inhibitor of extrinsic coagulation factor
4. Ingestion of a direct oral anticoagulant
Table 3 Representative underlying diseases and pathologies
that must be differentiated (Continued)
5. False prolongation: insufficient blood sample volume, addition
of an anti-coagulant
Decreased antithrombin activity
1. Liver failure, malnutrition
2. Extravasation due to inflammation (e.g., sepsis)
3. Degradation by granulocyte elastase (e.g., sepsis)
4. Congenital antithrombin deficiency
5. Drug-induced: L-asparaginase
Elevated TAT, SF, or F1+2
1. Thrombosis: deep vein thrombosis, pulmonary embolism
2. Some atrial fibrillation
Note: However, DIC may also occur with the above conditions and diseases
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For FDP, fibrinogen, and the PT ratio, the ranges and
point scoring methods were the same as those in the
JMHW criteria.
The AT activity was not included as a test item in
the JMHW criteria, but it has been adopted in the
new criteria. A score of 1 point is assigned for an AT
activity of ≤70 %.
The coagulation-fibrinolysis system molecular markers
were also not used as test items in the JMHW criteria,
but they have been adopted in the new criteria. One
point is given if these values are ≥2-fold the respective
upper limit of the standard range. In the cases of blood
sampling being difficult and route blood sampling,
values may be increased due to false high values [64],
and re-testing should be performed if the TAT and SF
data are markedly higher than the degrees of elevation
of FDP and D-dimer.
Liver failure includes acute liver failure and chronic
liver failure. For acute liver failure, we adopted the
terminology used in the diagnostic criteria created by
the Ministry of Health, Labour and Welfare’s Intract-
able Hepato-Biliary Diseases Study Group, which uses
the new “acute liver failure” in place of “fulminant
hepatitis” [98]. That is, acute liver failure was defined
Table 4 JSTH’s provisional draft DIC diagnostic criteria
Classification of type Basic Hematopoietic disorder Infectious
Platelet count (×104/μl) >12 0 p >12 0 p
8< –≤12 1 p 8< –≤12 1 p
5< –≤8 2 p 5< –≤8 2 p
≤5 3 p ≤5 3 p
≥30 % decrease w/in 24 h (*1) +1 p ≥30 % decrease w/in 24 h (*1) +1 p
FDP (μg/ml) <10 0 p <10 0 p <10 0 p
10≤ – <20 1 p 10≤ – <20 1 p 10 ≤ – <20 1 p
20≤ – <40 2 p 20≤ -<40 2 p 20≤ – <40 2 p
≥40 3 p ≥40 3 p ≥40 3 p
Fibrinogen (mg/dl) >150 0 p >150 0 p
100< –≤150 1 p 100< –≤150 1 p
≤100 2 p ≤100 2 p
Prothrombin time ratio <1.25 0 p <1.25 0 p <1.25 0 p
1.25≤ – <1.67 1 p 1.25≤ – <1.67 1 p 1.25≤ – <1.67 1 p
≥1.67 2 p ≥1.67 2 p ≥1.67 2 p
Antithrombin (%) >70 0 p >70 0 p >70 0 p
≤70 1 p ≤70 1 p ≤70 1 p
TAT, SF or F1+2 <2-fold of normal upper limit 0 p <2-fold of normal upper limit 0 p <2-fold of normal upper limit 0 p
≥2-fold of normal upper limit 1 p ≥2-fold of normal upper limit 1 p ≥2-fold of normal upper limit 1 p
Liver failure (*2) No 0 p No 0 p No 0 p
Yes ˗3 p Yes ˗3 p Yes ˗3 p
DIC diagnosis ≥6 p ≥4 p ≥6 p
p: points
• (*1): For a platelet count of >5 × 104/μL, points will be added if the time-course conditions of decrease are met (no points will be added for a platelet count of
≤5 × 104). The maximum score for the platelet count is 3 points
• For institutions that do not measure FDP (institutions that measure only D-dimer), 1 point will be added if D-dimer increases ≥2-fold the normal upper limit.
However, in principle, FDP should also be measured and re-evaluation performed after the results are in hand
• Prothrombin time ratio: If ISI is close to 1.0, INR will also be acceptable (However, there is no evidence supporting recommendation of the use of PT-INR for
diagnosis of DIC.)
• Thrombin-antithrombin complex (TAT), soluble fibrin (SF), prothrombin fragment 1+2 (F1+2): For blood sampling in difficult cases and route blood sampling,
false-high values may increase. Thus, in comparison with elevation of FDP and/or D-dimer, re-testing should be done if TAT and/or SF is markedly elevated.
Confirmation is needed even if the results on the same day are not in time
• Regardless of the presence or absence of DIC immediately after surgery, changes in DIC-like markers such as elevation of TAT, SF, FDP, or D-dimer or a decrease
in AT, may be observed, and judgment should be made with care
• (*2) Liver failure: Corresponds to “a prothrombin time activity of ≤40 % or an INR value of ≥1.5 due to severe liver dysfunction seen within eight weeks of onset
of initial symptoms following liver impairment that develops in a normal liver or a liver that is thought to exhibit normal liver function” (acute liver failure) or
“cirrhosis with a Child-Pugh classification of B or C (≥7 points)” (chronic liver failure) that may be viral or autoimmune in origin, drug-induced, or caused by
circulatory failure”
Even when DIC is strongly suspected but these diagnostic criteria are not met, there should be no interference with anti-coagulation therapy based on the
physician's judgment, but repeated evaluation is necessary
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as being caused by viral infection or autoimmune,
drug, or circulatory failure, and “liver failure develops
in a liver that is normal or is thought to exhibit nor-
mal function, and within eight weeks from the initial
appearance of symptoms the prothrombin time activ-
ity is ≤40 % or the INR value is ≥1.5 due to a high
degree of liver dysfunction”. Chronic liver failure was
defined as “Child-Pugh classification B or C cirrhosis
(≥7 points)” [99].
Other tests relating to DIC diagnosis, and their significance
Following diagnosis of DIC, testing should be performed
for the markers listed in Table 5, which are useful for
disease type classification and pathological assessment.
Points of difference between the JMHW criteria and the new
criteria
The new criteria make it clear that the algorithm should
be used, and the diagnostic criteria should be selected
based on the underlying pathology. Even in the JMHW
criteria, the scoring method is different for the leukemia
and non-leukemia groups, whereas the new criteria
make it clear that the diagnostic criteria should be se-
lectively used not only for the hematopoietic disorder
type but also the infectious type.
Regarding elimination of the platelet count from the
score for the hematopoietic disorder type, the JMHW
criteria did the same for the leukemia group, while the
new criteria also eliminate fibrinogen from the score for
the infectious type.
Although scoring was performed for the clinical symp-
toms and underlying disease in the JMHW criteria, it
was omitted from the new criteria for the above-
mentioned reasons.
Points were not added for a temporal decrease in the
platelet count in the JMHW criteria, but this was made
a 1-point item in the new criteria.
At present, AT activity was tentatively included in
the new criteria, and it was decided that validation
will be performed at multiple institutions. However,
even if AT activity is <70 %, the criteria do not rec-
ommend that administration of an AT preparation
always be carried out. The overall decision to admin-
ister an AT preparation always resides with the at-
tending physician.
Verification must be performed as to which coagulation-
fibrinolysis molecular markers are good, but diagnostic
criteria that incorporate molecular markers are completely
novel.
In the JMHW criteria, as well, 3 points are supposed
to be subtracted for liver cirrhosis and chronic hepa-
titis whose pathology approaches that of liver cirrhosis.
However, this has not necessarily been carried out
properly in clinical practice, and it had been one of
the causes of DIC misdiagnosis. For the new criteria,
we took into account that, on that background, the
criteria had not conventionally been applied to cases
of fulminant hepatitis, and we incorporated a 3-point
reduction for liver failure in the table in the new
criteria.
Conclusion
DIC, based on the presence of underlying disease, has a
common pathology in that systemic, persistent, marked
coagulation activation is caused. However, there are
many points of difference in terms of the degree of fi-
brinolytic activation, the way in which clinical symptoms
manifest, and the degree of formation of pathological
blood clots. In regard to diagnosis of DIC, it also makes
sense to apply diagnostic criteria selectively depending
on the pathology.
DIC diagnostic criteria have great significance in re-
gard to patients’ treatment and prognosis. The JMHW
criteria have been extensively used in Japan, but it has
been pointed out that they have many problems, such as
their poor sensitivity in diagnosing DIC due to infec-
tions. Meanwhile, the JAAM criteria are effective for
diagnosing DIC due to infection, but they are not applic-
able to all underlying diseases.
In this paper, we have presented the provisional draft
DIC diagnostic criteria of the Japanese Society on
Thrombosis and Hemostasis. These new criteria have
many laudable aspects, including selective use of diag-
nostic criteria depending on the underlying disease, in-
corporation of molecular markers and antithrombin, and
measures to reduce misdiagnoses. We look forward to
further refinement and improvement of these new cri-
teria in the future.





The higher the values, the greater the
fibrinolytic activation
α2 plasmin inhibitor (α2PI) This is consumed and decreases due to
fibrinolytic activation. However, it is also
decreased by liver failure alone, and it is
elevated in acute inflammatory diseases.
Protein C (PC) Low values correlate with a poor prognosis.
However, it is also decreased by vitamin K
deficiency and/or liver failure alone.
Plasminogen activator
inhibitor-1 (PAI-1)
High values in infectious-type DIC correlate
with a poor prognosis.
HMGB-1 High values correlate with a poor prognosis.
e-XDP Both low and markedly elevated values in
infectious-type DIC correlate with a
poor prognosis.
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